We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+21.36%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$567M
AUM Growth
+$88.3M
Cap. Flow
+$6.93M
Cap. Flow %
1.22%
Top 10 Hldgs %
70.26%
Holding
36
New
5
Increased
6
Reduced
13
Closed
6

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$45.2M
2
CNCE
Concert Pharmaceuticals, Inc.
CNCE
+$18M
3
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$14.1M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$8.25M
5
LOXO
Loxo Oncology, Inc
LOXO
+$6.69M

Top Sells

Rank Stock Value
1
LGND icon
Ligand Pharmaceuticals
LGND
+$20.6M
2
CASC
Cascadian Therapeutics, Inc.
CASC
+$12M
3
CCXI
ChemoCentryx, Inc.
CCXI
+$8.21M
4
EXEL icon
Exelixis
EXEL
+$7.23M
5
FPRX
Five Prime Therapeutics, Inc.
FPRX
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 62.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
26
DELISTED
Vaxart
VXRT
$726K 0.13%
31,889
– –
AKAO
27
DELISTED
Achaogen Inc
AKAO
$643K 0.11%
106,700
-29,900
-22% -$185K
APTO
28
DELISTED
Aptose Biosciences, Inc.
APTO
$538K 0.1%
234
-136
-37% -$356K
BLRX
29
BioLineRX
BLRX
$11.7M
– –
-2,502
Closed -$3.17M
LGND icon
30
Ligand Pharmaceuticals
LGND
$5.94B
– –
-428,145
Closed -$20.6M
LITS
31
Lite Strategy Inc
LITS
$33.6M
– –
-30,000
Closed -$1.07M
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-9,014
Closed -$4.64M
SPHS
33
DELISTED
Sophiris Bio, Inc.
SPHS
– –
-1,060,283
Closed -$614K
KBIO
34
DELISTED
KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
– –
-145,250
Closed -$569K
1
2

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2015 Portfolio in Review

As of Q2 2015, BVF Inc held 36 positions worth $567M, up 18% from $478M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

BVF Inc's Q2 2015 filing shows 5 new, 6 increased, 13 reduced and 6 closed positions. Its largest new stake was Blueprint Medicines: 1,582,408 shares worth $41.9M. The largest sale was Ligand Pharmaceuticals, an estimated $20.6M.

By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 63% a quarter earlier.

  • BVF Inc's largest Q2 2015 buy was Blueprint Medicines: 1,582,408 shares worth $41.9M.
  • BVF Inc added most to Concert Pharmaceuticals, Inc. in Q2 2015, an estimated $18M increase.
  • BVF Inc's biggest Q2 2015 reduction was Cascadian Therapeutics, Inc., cutting an estimated $12M.
  • BVF Inc fully exited Ligand Pharmaceuticals in Q2 2015, selling an estimated $20.6M.
  • BVF Inc's ten largest holdings make up 70% of its $567M portfolio in Q2 2015.
  • BVF Inc opened 5 new positions and closed 6 in Q2 2015.
  • BVF Inc's portfolio value rose 18% quarter-over-quarter to $567M.

Based on BVF Inc's 13F filing for Q2 2015, filed 14 Aug 2015.